The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, GRK5 and CSNK2A1, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of metabolic diseases. The invention is further related to methods of treatment of metabolic diseases, particularly diabetes mellitus type 2.
